Hematopoietic SCT for peripheral T-cell lymphoma

Bone Marrow Transplantation

Volumn 42, Issue 12, 2008, Pages 773-781

  Gutierrez A ^a   Caballero, M D ^b   Perez Manga G ^c   Rodriguez, J ^c  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; MELPHALAN; MESNA; METHOTREXATE; PREDNISONE; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER RELAPSE; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG MEGADOSE; GRAFT REJECTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; REVIEW; TREATMENT OUTCOME; WHOLE BODY RADIATION;

DRUG RESISTANCE, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 58149195253     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.332     Document Type: Review

References (47)

1. Chan JK. Peripheral T-cell and NK-cell neoplasms: An integrated approach to diagnosis. Mod Pathol 1999; 12: 177-199.
2. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
3. MeInyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997; 89: 4514-4520.
4. Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): Results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002; 13: 140-149.
5. AbouYabis AN, Shenoy PJ, Flowers C, Lechowicz MJ. Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: A comprehensive meta-analysis. Blood 2007; 110: 3452.
6. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15: 1467-1475.
7. Bierman P, Vose JM, Bociek RG, Loberiza F, Bast M, Weisenburger DD et al. Outcome of limited-stage peripheral T-cell lymphoma: Results from the Nebraska Lymphoma Study Group. Blood 2007; 110: 3451.
8. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM et al ALK-negative anaplastic large-cell lymphoma (ALCL) is clinically and immunophenotypically different from both ALK-positive ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496-5504.
9. Escalon MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: The MD Anderson Cancer Center experience. Cancer 2005; 103: 2091-2098.
10. Blystad AK, Enblad G, Kvaloy S, Berglund A, Delabie J, Holte H et al High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001; 27: 711-716.
11. Caballero MD, Perez-Simon JA, Iriondo A, Lahuerta JJ, Sierra J, Marin J et al. High-dose therapy in diffuse large cell lymphoma: Results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003; 14: 140-151.
12. Kewalramani T, Zelenetz AD, Teruya-Feldstein J, Hamlin P, Yahalom J, Horwitz S et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006; 134: 202-207.
13. Feyler S, Prince HM, Pearce R, Towlson K, Nivison-Smith I, Schey S et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: A BSBMT and ABMTRR study. Bone Marrow Transplant 2007; 40: 443-450.
14. Rodriguez J, Conde E, Gutierrez A, Lahuerta JJ, Arranz R, Sureda A et al. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 2007; 92: 1067-1074.
15. Rodriguez J, Munsell M, Yazji S, Hagemeister FB, Younes A, Andersson B et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001; 19: 3766-3770.
16. Song KW, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: Variable outcome according to pathological sub-type. Br J Haematol 2003; 120: 978-985.
17. Jantunen E, Wiklund T, Juvonen E, Putkonen M, Lehtinen T, Kuittinen O et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: A nation-wide survey. Bone Marrow Transplant 2004; 33: 405-410.
18. Smith SD, Bolwell BJ, Rybicki LA, Brown S, Dean R, Kalaycio M et al Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant 2007; 40: 239-243.
19. Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J et al The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: The Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007; 18: 652-657.
20. Rodriguez J, Caballero MD, Gutierrez A, Gandarillas M, Sierra J, Lopez-Guillermo A et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica 2003; 88: 1372-1377.
21. Rodriguez J, Caballero MD, Gutierrez A, Marin J, Lahuerta JJ, Sureda A et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: The GELTAMO experience. Ann Oncol 2003; 14: 1768-1775.
22. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U et al Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474-2479.
23. Rodriguez J, Conde E, Gutierrez A, Arranz R, Gandarillas M, Leon A et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: The GELTAMO experience. Eur J Haematol 2007; 78: 290-296.
24. Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: Complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 218-224.
25. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20: 1533-1538.
26. Reimer P, Ruediger T, Weissinger F, Mueller-Hermelink HK, Engert A, Einsele H et al. Different outcome for angioimmunoblastic T-cell lymphoma (AIL) and peripheral T-cell lymphoma unspecified (PTCL-U) following upfront autologous stem cell transplantation. Blood 2006; 108: 5431a.
27. d'Amore F, Relander T, Lauritzsen G, Jantunen E, Hagberg H, Anderson H et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphomas (PTCL) - a Phase II Study of the Nordic Lymphoma Group (NLG). Blood 2006; 108: 401a.
28. Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J et al Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: A prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007; 79: 32-38.
29. Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008; 19: 958-963.
30. Reimer P, Schertlin T, Rüdiger T, Geissinger E, Roth S, Kunzmann V et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: First results of a prospective multicenter study. Hematol J 2004; 5 304-311.
31. Reimer P, Rüdiger T, Einsele H, Geissinger E, Weissinger F, Nerl C et al. Autologous stem cell transplantation (autoSCT) as first-line therapy in peripheral T cell lymphomas (PTCL): Results of a prospective multicenter study. J Clin Oncol 2008; 26: 8515.
32. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, Garcia-Conde J et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Gruppo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395-1404.
33. Mercadal S, Lopez-Guillermo A, Briones J, Xicoy B, Pedro C, Escoda L et al. Is there a role for autologous stem-cell transplantation (ASCT) in peripheral T-cell lymphoma (PTCL)? Final results of a prospective phase II study from the GELCAB. Blood 2006; 108: 3070a.
34. d'Amore F. High-dose therapy and autologous stem cell transplant as first line treatment in peripheral T-cell lymphomas. Ann Oncol 2005; 16: V15-v26.
35. Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172-2176.
36. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: A study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008; 26: 2264-2271.
37. Wulf GG, Hasenkamp J, Jung W, Chapuy B, Truemper L, Glass B. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2005; 36: 271-273.
38. Tanosaki R, Kim S, Yamazaki S, Fukuda T, Mori S, Heike Y et al. A retrospective single institute analysis of 127 lymphoma patients who underwent allogeneic stem cell transplantation: Impact on peripheral T-cell lymphoma (PTCL) including ATLL. Blood 2006; 108: 3031.
39. Zain J, Palmer J, Tsai N, Popplewell L, Nadamanee A, Krishnan A et al Clinical outcomes of patients with T cell NHL undergoing allogeneic stem cell transplant. Blood 2006; 108: 3026.
40. O'Leary HM, Savage KJ, Toze CL, Connors JM, Gascoyne RD, Mourad YA et al. Allogeneic stem cell transplantation as treatment for relapsed and high-risk peripheral T-Cell lymphoma. Blood 2007; 110: 3040.
41. Günther A, Schade H, Humpe A, Gahn B, Claviez A, Schrauder A et al BEAM-alemtuzumab followed by allogeneic SCT is a feasible and highly efficient treatment strategy in relapsed or refractory T-NHL. Bone Marrow Transplant 2008; 41 (S1): S244.
42. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Blum KA et al. Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas: Evidence of graft-versus-T cell lymphoma effect. Biol Blood Marrow Transplant 2008; 14: 480-483.
43. Kim JG, Sohn SK, Chae YS, Kim DH, Baek JH, Lee KB et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 2006; 58: 35-39.
44. Kurzrock R, Ravandi F. Purine analogues in advanced T-cell lymphoid malignancies. Semin Hematol 2006; 43 (2 Suppl 2): S27-S34.
45. O'Connor OA, Hamlin PA, Portlock C, Moskowitz CH, Noy A, Straus DJ et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007; 139: 425-428.
46. Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A et al Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110: 2316-2323.
47. Foss F. Clinical experience with denileukin diftitox (ONTAK). Semin Oncol 2006; 33 (1 Suppl 3): S11-S16.